Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Ulrich Kutschera
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and behavioral changes. There are currently no known treatments or medications for AD. Nitric oxide (NO) has long been regarded as a component of the neurotoxic insult brought on by Alzheimer's disease neuroinflammation.
However, this perception is being altered by focusing on early developments, prior to the onset of cognitive symptoms. This has brought to light NO's compensatory, neuroprotective function, which increases neuronal excitability to safeguard synapses. Modulation of voltage-gated potassium channel activity (Kv7 and Kv2) is one potential mechanism by which NO can increase excitability. An important next step for the field is to determine the ionic mechanisms and signaling pathways that mediate this protection. A potential therapeutic option for preventing synapse loss early in disease could be found by harnessing the protective function of NO and related signaling pathways.